DE DUVE INSTITUTE AISBL

Their core work

The de Duve Institute is a biomedical research center in Brussels focused on understanding the molecular and cellular mechanisms of cancer, vascular diseases, and developmental biology. Their work spans cancer immunotherapy, gene therapy for lymphatic disorders, 3D bioprinting of tissue models, and immunoprofiling of tumor microenvironments. They contribute deep expertise in translational research — bridging fundamental biology with therapeutic strategies for diseases like breast cancer, vascular anomalies, and lymphedema. Named after Nobel laureate Christian de Duve, the institute operates at the intersection of genetics, cell biology, and experimental medicine.

What they specialise in

How they've shifted over time

In their earlier H2020 projects (2018–2019), the institute focused on cancer metabolism, patient stratification through systems biology, and developmental biology including 3D bioprinting of pancreatic tissue. By 2019–2021, their work shifted toward therapeutic interventions — gene therapy for lymphedema, molecular therapy for vascular anomalies, and engineering immune environments for adoptive cell therapy. The trajectory shows a clear move from understanding disease mechanisms toward developing actual treatment strategies.

The institute is moving from disease characterization toward therapeutic development, particularly in gene therapy and immune-engineering — expect future projects in advanced therapy medicinal products (ATMPs) and personalized cancer treatment.

How they like to work

The de Duve Institute primarily joins consortia as a specialist partner (5 of 6 projects), contributing focused biological and translational expertise to larger teams. They coordinated one project (V.A. Cure) in rare vascular diseases, indicating leadership capacity in their core niche. With 81 unique partners across 17 countries, they operate as a well-connected node in European biomedical research networks, comfortable working in large multidisciplinary consortia rather than small bilateral collaborations.

Broad European network spanning 81 partners across 17 countries, reflecting participation in large health-sector consortia. Their connections are distributed across Western and Central Europe, with no single dominant geographic cluster.

What sets them apart

The de Duve Institute bridges fundamental cell biology with translational medicine in a way few research centers of its size can. Their rare combination of vascular biology, cancer immunotherapy, and 3D tissue engineering expertise makes them a versatile partner for projects that need deep mechanistic understanding paired with therapeutic ambition. For consortium builders, they offer a credible Belgian partner with a Nobel-legacy reputation and demonstrated ability to contribute across multiple disease areas without being locked into a single clinical application.

Highlights from their portfolio

• V.A. Cure
  Their only coordinated project — a rare disease initiative on vascular anomalies combining genetics, imaging, and molecular therapy, signaling their strongest area of institutional leadership.
• TheraLymph
  Largest single EC contribution (EUR 608,335) and a gene therapy project tackling lymphedema — represents their push toward advanced therapeutics.
• IMMUcan
  Large-scale cancer immunoprofiling project using deep cytometry, RNA-seq, and microbiome analysis across multiple cancer types — showcases their high-throughput analytical capabilities.